Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells.

Rausch, Jessica L; Ali, Areej A; Lee, Donna M; Gebreyohannes, Yemarshet K; Mehalek, Keith R; Agha, Aya; Patil, Sneha S; Tolstov, Yanis; Wellens, Jasmien; Dhillon, Harbir S; Makielski, Kathleen R; Debiec-Rychter, Maria; Schöffski, Patrick; Wozniak, Agnieszka; Duensing, Anette

Rausch, Jessica L; Ali, Areej A; Lee, Donna M; Gebreyohannes, Yemarshet K; Mehalek, Keith R; Agha, Aya; Patil, Sneha S; Tolstov, Yanis; Wellens, Jasmien; Dhillon, Harbir S; Makielski, Kathleen R; Debiec-Rychter, Maria; Schöffski, Patrick; Wozniak, Agnieszka; Duensing, Anette.

Afiliación

Rausch JL; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Ali AA; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Lee DM; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Gebreyohannes YK; Departments of Oncology and General Medical Oncology, University Hospitals Leuven and KU Leuven Cancer Institute, Leuven, Belgium.
Mehalek KR; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Agha A; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Patil SS; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Tolstov Y; Molecular Urooncology, University of Heidelberg School of Medicine, Heidelberg, Germany.
Wellens J; Departments of Oncology and General Medical Oncology, University Hospitals Leuven and KU Leuven Cancer Institute, Leuven, Belgium.
Dhillon HS; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Makielski KR; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Debiec-Rychter M; Department of Human Genetics, University Hospitals Leuven and KU Leuven, Leuven, Belgium.
Schöffski P; Departments of Oncology and General Medical Oncology, University Hospitals Leuven and KU Leuven Cancer Institute, Leuven, Belgium.
Wozniak A; Departments of Oncology and General Medical Oncology, University Hospitals Leuven and KU Leuven Cancer Institute, Leuven, Belgium.
Duensing A; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. aduensin@pitt.edu.

Sci Rep ; 10(1): 5178, 2020 03 20.

Article en En | MEDLINE | ID: mdl-32198455

Asunto(s)

Tumores del Estroma Gastrointestinal/tratamiento farmacológico; Tumores del Estroma Gastrointestinal/metabolismo; Complejo de la Endopetidasa Proteasomal/efectos de los fármacos; Animales; Antineoplásicos/farmacología; Apoptosis/efectos de los fármacos; Compuestos de Boro/farmacología; Ácidos Borónicos/farmacología; Línea Celular Tumoral; Resistencia a Antineoplásicos/genética; Femenino; Glicina/análogos & derivados; Glicina/farmacología; Humanos; Mesilato de Imatinib/farmacología; Masculino; Ratones; Ratones Desnudos; Oligopéptidos/farmacología; Complejo de la Endopetidasa Proteasomal/fisiología; Inhibidores de Proteínas Quinasas/farmacología; Proteínas Proto-Oncogénicas c-kit/genética; Transducción de Señal/efectos de los fármacos; Treonina/análogos & derivados; Treonina/farmacología; Ensayos Antitumor por Modelo de Xenoinjerto

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Tumores del Estroma Gastrointestinal / Complejo de la Endopetidasa Proteasomal Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans / Male Idioma: En Revista: Sci Rep Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google